What is Astromech?
Astromech operates at the vanguard of the AI biotechnology sector, specializing in the development of sophisticated systems designed to model and interpret the fundamental code of life. By integrating machine learning algorithms with evolutionary biology and multi-omics data, the company provides researchers with the tools necessary to decode complex genetic systems. This capability allows for the precise prediction of biological behavior, effectively accelerating the pace of discovery in medicine, genetics, and synthetic biology. As an enterprise-level player, Astromech is transforming how biological data is processed, moving beyond traditional analytical methods to offer a more predictive and scalable approach to life sciences innovation.
How much funding has Astromech raised?
Astromech has raised a total of $60.5M across 3 funding rounds:
Stock/Share Issuance
$30M
Stock/Share Issuance
$10.5M
Other Financing Round
$20M
Stock/Share Issuance (2025): $30M, investors not publicly disclosed
Stock/Share Issuance (2026): $10.5M, investors not publicly disclosed
Other Financing Round (2026): $20M supported by Builders VC and Peak6 Investments
Key Investors in Astromech
Builders VC
Builders VC is a venture capital firm focused on modernizing antiquated industries by investing in innovative technologies and solutions that reshape complex systems.
Peak6 Investments
Peak6 Investments LLC is a private equity firm specializing in financial markets infrastructure, trading, and investment management solutions.
What's next for Astromech?
With this recent strategic investment, Astromech is well-positioned to expand its computational infrastructure and deepen its research capabilities. The company is expected to focus on scaling its multi-omics data processing engines, which are essential for high-throughput synthetic biology applications. Furthermore, the influx of capital will likely support the expansion of its commercial partnerships, enabling the firm to integrate its predictive models into broader clinical and industrial workflows. As the biotechnology landscape continues to shift toward data-centric discovery, Astromech's ability to bridge the gap between raw genetic data and actionable biological insights will be a primary driver of its long-term market valuation and strategic growth.
See full Astromech company page
